These products directly enter the pathways of intermediary metabolism, resulting either in the synthesis of Glucose or lipids, or in the production of energy through their oxidation to CO2 and H2O by the citric acid cycle.
The catabolism of amino acids found in the proteins involves the removal of alpha amino groups, followed by the breakdown of the resulting carbon skeletons.
The metabolism of amino acids involves biosynthesis, catabolism, conversion to specialized products, and the conversion of amino acids to intermediates of metabolism.
Plasma and urinary levels of leucine, isoleucine, valine, α-keto acids, and α-hydroxy acids (reduced α-keto acids) are elevated in maple syrup urine disease.
Phenylalanine is first converted to tyrosine in the body and Hyperphenylalaninemias arise from defects in phenylalanine hydroxylase itself (type I, classic phenylketonuria or PKU), in dihydrobiopterin reductase (types II and III), or in dihydrobiopterin biosynthesis (types IV and V).
Maple syrup urine disease is characterized by the odor of urine in maple syrup urine disease (branched-chain ketonuria) and involves the -keto acid decarboxylase complex.
Agents, thought to be responsible for mental retardation in phenylketonuric subjects, include phenylalanine, dietary sources of phenylalanine, and products of phenylalanine catabolism.
Prompt replacement of dietary protein by an amino acid mixture that lacks leucine, isoleucine, and valine averts brain damage and early mortality in maple syrup urine disease.
Amino acids synthesized from intermediates of metabolism include Alanine, Aspartate, Glutamate, which are synthesized by transfer of an amino group to the α-keto acids.